Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FBLG Stock Forecast 2026-2027
$1.52
Current Price
$6.95M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to FBLG Price Targets
+1,873.7%
To High Target of $30.00
+1,150.0%
To Median Target of $19.00
+426.3%
To Low Target of $8.00
FBLG Price Momentum
-1.3%
1 Week Change
-70.1%
1 Month Change
-94.0%
1 Year Change
-66.2%
Year-to-Date Change
-95.0%
From 52W High of $30.60
+47.6%
From 52W Low of $1.03
📊 TOP ANALYST CALLS
Did FBLG Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if FibroBiologics is one of their latest high-conviction picks.
Latest FBLG Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, FBLG has a bullish consensus with a median price target of $19.00 (ranging from $8.00 to $30.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.52, the median forecast implies a 1,150.0% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 426.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FBLG Analyst Ratings
2
Buy
1
Hold
0
Sell
FBLG Price Target Range
Low
$8.00
Average
$19.00
High
$30.00
Current: $1.52
Latest FBLG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FBLG.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2026 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $8.00 |
| Mar 26, 2026 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $N/A |
| Mar 12, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $7.00 |
| Feb 26, 2026 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $4.00 |
| Feb 25, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $7.00 |
| Jan 6, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Jan 2, 2026 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $5.00 |
| Nov 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Nov 5, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $5.00 |
| Nov 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Sep 12, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Sep 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Aug 5, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $12.00 |
| Aug 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Jul 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Jul 9, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Jun 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| May 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Apr 9, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Apr 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
Fibrobiologics Inc. (FBLG) Competitors
The following stocks are similar to FibroBiologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fibrobiologics Inc. (FBLG) Financial Data
Fibrobiologics Inc. has a market capitalization of $6.95M with a P/E ratio of -3.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -419.4%.
Valuation Metrics
Market Cap
$6.95M
Enterprise Value
$2.69M
P/E Ratio
-3.7x
PEG Ratio
-0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+95.3%
Current Ratio
3.6x
Debt/Equity
39.1x
ROE
-419.4%
ROA
-79.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fibrobiologics Inc. (FBLG) Business Model
About Fibrobiologics Inc.
What They Do
Biotechnology company specializing in regenerative medicine.
Business Model
Fibrobiologics Inc. generates revenue through the development and commercialization of fibroblast-based therapies for repairing and regenerating damaged tissues. The company invests heavily in research and development to create innovative treatments for chronic wounds, degenerative diseases, and age-related conditions, addressing significant unmet medical needs in the healthcare sector.
Additional Information
The company's focus on fibroblast cells positions it at the forefront of regenerative medicine, with the potential to make impactful advancements in patient care. As a player in the broader biotechnology industry, Fibrobiologics could contribute to the evolution of next-generation therapies that enhance patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Mr. Peter O'Heeron
Country
United States
IPO Year
N/A
Website
fibrobiologics.comFibrobiologics Inc. (FBLG) Latest News & Analysis
Latest News
Quick Summary
FibroBiologics, Inc. (Nasdaq: FBLG) has confirmed compliance with Nasdaq listing requirements, including stockholders' equity over $2.5 million and a minimum bid price of $1.00.
Why It Matters
FibroBiologics' compliance with Nasdaq listing requirements reassures investors about its market stability and operational health, potentially boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Preclinical models show potential to restore thymic function lost with aging, which may lower risks of cancer, autoimmune diseases, infections, and improve vaccine efficacy.
Why It Matters
The potential to restore thymic function could lead to breakthroughs in age-related health treatments, impacting biotech investments and the pharmaceutical market significantly.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FibroBiologics (NASDAQ: FBLG) closed a public offering of 2.27 million shares and warrants, priced at $1.32 each. Warrants are exercisable after stockholder approval and last five years.
Why It Matters
FibroBiologics raised capital through a public offering, enhancing liquidity for R&D. The issuance of warrants could influence share price and investor sentiment based on future approval and performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FibroBiologics (Nasdaq: FBLG) has completed the first batch of its CYWC628 drug product, compliant with FDA standards, for upcoming first-in-human clinical trials.
Why It Matters
Successful completion of CYWC628 manufacturing marks a key milestone for FibroBiologics, signaling progress toward clinical trials and potential future revenue, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FibroBiologics, Inc. announced a public offering of 2,272,728 shares at $1.32 each, including warrants. Closing is expected by April 2, 2026, pending stockholder approval.
Why It Matters
FibroBiologics is raising capital through a public offering, which could dilute existing shares but also fund its development pipeline, impacting stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement
27 days ago
Quick Summary
FibroBiologics, Inc. (Nasdaq: FBLG) announced a 1-for-20 reverse stock split of its common stock, effective March 26, 2026, as approved by its Board of Directors.
Why It Matters
The reverse stock split indicates a restructuring aimed at increasing the stock price, which may attract more institutional investors and stabilize the company’s market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FBLG Stock
What is Fibrobiologics Inc.'s (FBLG) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Fibrobiologics Inc. (FBLG) has a median price target of $19.00. The highest price target is $30.00 and the lowest is $8.00.
Is FBLG stock a good investment in 2026?
According to current analyst ratings, FBLG has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FBLG stock?
Wall Street analysts predict FBLG stock could reach $19.00 in the next 12 months. This represents a 1,150.0% increase from the current price of $1.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fibrobiologics Inc.'s business model?
Fibrobiologics Inc. generates revenue through the development and commercialization of fibroblast-based therapies for repairing and regenerating damaged tissues. The company invests heavily in research and development to create innovative treatments for chronic wounds, degenerative diseases, and age-related conditions, addressing significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for FBLG Fibrobiologics Inc.?
The highest price target for FBLG is $30.00 from at , which represents a 1,873.7% increase from the current price of $1.52.
What is the lowest forecasted price for FBLG Fibrobiologics Inc.?
The lowest price target for FBLG is $8.00 from Matthew Caufield at HC Wainwright & Co., which represents a 426.3% increase from the current price of $1.52.
What is the overall FBLG consensus from analysts for Fibrobiologics Inc.?
The overall analyst consensus for FBLG is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are FBLG stock price projections?
Stock price projections, including those for Fibrobiologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 5:25 AM UTC